Clinical trial
A Phase 1, Randomized, Double-blind Study to Compare the Pharmacokinetics, Between BAT3306 and Keytruda® (Pembrolizumab) in Participants With Stage IB-IIIA Non-small Cell Lung Cancer Following Complete Resection
NCT07180862 is registered in ClinicalTrials.gov with Bio-Thera Solutions as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-blind Study to Compare the Pharmacokinetics, Between BAT3306 and Keytruda® (Pembrolizumab) in Participants With Stage IB-IIIA Non-small Cell Lung Cancer Following Complete Resection
- Lead sponsor
- Bio-Thera Solutions
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- October 14, 2025
- Completion date
- November 30, 2027
- Enrollment
- 160 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.